Cellectis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Cellectis and buy or sell other stocks, ETFs, and their options commission-free!

About CLLS

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. 

CEO
André Choulika
CEOAndré Choulika
Employees
229
Employees229
Headquarters
Paris, Ile-de-France
HeadquartersParis, Ile-de-France
Founded
2000
Founded2000
Employees
229
Employees229

CLLS Key Statistics

Market cap
205.98M
Market cap205.98M
Price-Earnings ratio
-4.14
Price-Earnings ratio-4.14
Dividend yield
Dividend yield
Average volume
10.68K
Average volume10.68K
High today
$2.79
High today$2.79
Low today
$2.72
Low today$2.72
Open price
$2.76
Open price$2.76
Volume
4.20K
Volume4.20K
52 Week high
$5.48
52 Week high$5.48
52 Week low
$2.48
52 Week low$2.48

CLLS News

TipRanks 5h
Cellectis Updates Share Capital and Voting Rights as of July 31, 2026

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

TipRanks 6d
Cellectis Sets August 6 Date to Release Q2 2026 Results - TipRanks

...

Cellectis Sets August 6 Date to Release Q2 2026 Results - TipRanks

Analyst ratings

86%

of 7 ratings
Buy
85.7%
Hold
14.3%
Sell
0%

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.